Panacea Life Sciences Holdings annual free cash flow
2014
2015
2016
2018
2019
2020
2021
2022
2023
Panacea Life Sciences Holdings Free Cash Flow (FCF) History (PLSH)
Panacea Life Sciences Holdings reported −$1.6M in free cash flow for fiscal 2023, an increase of $1.1M from the previous fiscal year, with a free cash flow margin of −66.66%.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-12-31 | −$1.6M | $1.1M | — | −66.66% |
| 2022 | 2022-12-31 | −$2.6M | $1.4M | — | −162.47% |
| 2021 | 2021-12-31 | −$4.1M | $3.6M | — | −198.34% |
| 2020 | 2020-12-31 | −$7.6M | −$1.4M | — | −84.80% |
| 2019 | 2019-12-31 | −$6.3M | −$5.8M | — | −1818.88% |
| 2018 | 2018-12-31 | −$465,755 | $426,493 | — | — |
| 2016 | 2016-12-31 | −$892,248 | −$252,228 | — | — |
| 2015 | 2015-12-31 | −$640,020 | −$234,352 | — | −300478.87% |
| 2014 | 2014-12-31 | −$405,668 | — | — | −47613.62% |
Panacea Life Sciences Holdings quarterly free cash flow
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q1.24
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2024 | 2024-03-31 | −$362,090 | $476,347 | — | −34.27% |
| Q2 2023 | 2023-06-30 | −$492,666 | $244,670 | — | −123.44% |
| Q1 2023 | 2023-03-31 | −$329,071 | $116,697 | — | −48.57% |
| Q4 2022 | 2022-12-31 | −$621,842 | $617,496 | — | −191.46% |
| Q3 2022 | 2022-09-30 | −$838,437 | −$72,133 | — | −228.93% |
| Q2 2022 | 2022-06-30 | −$737,336 | $506,563 | — | −157.06% |
| Q1 2022 | 2022-03-31 | −$445,768 | $436,229 | — | −95.56% |
| Q4 2021 | 2021-12-31 | −$1.2M | $3.1M | — | −107.02% |
| Q3 2021 | 2021-09-30 | −$766,304 | $3.1M | — | −130.31% |
| Q2 2021 | 2021-06-30 | −$1.2M | $4.6M | — | −396.78% |
| Q1 2021 | 2021-03-31 | −$881,997 | −$717,714 | — | — |
| Q4 2020 | 2020-12-31 | −$4.3M | −$3.6M | — | −639.78% |
| Q3 2020 | 2020-09-30 | −$3.9M | −$2.2M | — | −290.40% |
| Q2 2020 | 2020-06-30 | −$5.9M | −$3.8M | — | −95.02% |
| Q1 2020 | 2020-03-31 | −$164,283 | $1.7M | — | −19.65% |
| Q4 2019 | 2019-12-31 | −$763,616 | −$705,785 | — | −448.18% |
| Q3 2019 | 2019-09-30 | −$1.7M | −$1.7M | — | −2899.55% |
| Q2 2019 | 2019-06-30 | −$2.0M | −$2.0M | — | −2024.38% |
| Q1 2019 | 2019-03-31 | −$1.9M | −$1.6M | — | −11653.66% |
| Q4 2018 | 2018-12-31 | −$57,831 | $348,985 | — | — |
| Q3 2018 | 2018-09-30 | −$73,918 | $55,364 | — | — |
| Q2 2018 | 2018-06-30 | −$38,726 | $150,883 | — | — |
| Q1 2018 | 2018-03-31 | −$295,280 | −$128,739 | — | — |
| Q4 2016 | 2016-12-31 | −$406,816 | −$337,674 | — | — |
| Q3 2016 | 2016-09-30 | −$129,282 | −$47,386 | — | — |
| Q2 2016 | 2016-06-30 | −$189,609 | $219,738 | — | — |
| Q1 2016 | 2016-03-31 | −$166,541 | −$83,862 | — | — |
| Q4 2015 | 2015-12-31 | −$69,142 | −$54,009 | — | −32461.03% |
| Q3 2015 | 2015-09-30 | −$81,896 | — | — | — |
| Q2 2015 | 2015-06-30 | −$409,347 | — | — | — |
| Q1 2015 | 2015-03-31 | −$82,679 | — | — | — |
| Q3 2014 | 2014-09-30 | −$15,133 | — | — | −7104.69% |
Panacea Life Sciences Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$465,755 to −$1.6M, a net decrease of $1.1M. Panacea Life Sciences Holdings's latest reported quarter, Q1 2024, generated −$362,090 in free cash flow, an increase of $476,347 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Panacea Life Sciences Holdings filings at SEC.gov ↗